Galectin Therapeutics Inc
galectintherapeutics.comWhat Do They Do?
Develops drug candidates that target galectin proteins, including belapectin for liver cirrhosis associated with MASH and certain cancers.
10-K for FY2025, filed Mar 31, 2026We are a clinical stage biopharmaceutical company engaged in drug research and development to create new therapies for fibrotic disease…View ↗
Our lead galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and…View ↗
We have one new proprietary chemical entity (NCE) in development, belapectin, which has shown promise in preclinical and clinical studies…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 31, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 14, 2026
−$9.1MView ↗
- ▲ +21% (Loss)
- vs −$7.5M in Q2 FY2025
-
Aug 14, 2026
Galectin agreed with the FDA on key elements of its planned Phase 3 trial.
The company plans to submit the trial protocol in the third quarter of 2026.
Sources
8-K, filed Aug 14, 2026
Registrational Phase 3 trial protocol submission for belapectin in advanced MASH cirrhosis with portal hypertension is anticipated in 3Q…View ↗
Loading...
